Pinterest drops after Q4 revenue forecast falls short of estimates
Shares of image-sharing platform Pinterest PINS.N decline 18.6% to $26.8 premarket
PINS forecasts Q4 revenue between $1.31 bln and $1.34 bln, with the midpoint falling below analysts' average estimate of $1.34 bln according to data compiled by LSEG
At least six brokerages cut PT on stock post results, with Jefferies' new PT of $28 among the lowest on Wall Street
Market uncertainty continues with addition of new tariff in Q4 impacting the home furnishings category - CFO
Reports Q3 rev of $1.05 bln, up 17% YoY; revenue for U.S. and Canada (UCAN) region rises the least, up 9%
Q3 adj. EPS of 38 cents misses estimates of 42 cents
"Performance has been fine, but we struggle to see a catalyst to drive the business and accelerate growth," Piper Sandler analysts said in a note
As of last close, PINS up more than 13% YTD
Related Articles
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemic
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?
The Tariff Refund Drama Begins: Five Major Impacts If Trump Loses the Supreme Court Case
TradingKey - A landmark legal battle with clear undertones of “small business vs. government” will unfold at the U.S. Supreme Court on November 5, a case President Donald Trump has called “the most important in American history.” The ruling will directly determine the legality of Trump’s signature
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.
